Spin-offs

ProCURE fosters forefront cancer research at the same time that encourages innovation and technology transfer. We are particularly proud of having been the incubator for the launching of 4 spin-off companies,  Xenopat and AtG, currently active, and Metabostemness and VCN Biosciences founded by four of our group leaders

Logo Xenopat

Xenopat

Advanced Preclinical Services
Xenopat offers researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available. Xenopat offers researchers the OrthoXenoBank®, which is composed of several orthotopic models of different tumor types (orthoxenografts®), characterized at histological and genetic levels, with different sensitivity to diverse chemotherapies.

Personalized Cancer
TreatmentXenopat offers healthcare professionals and patients the most advanced technology in order to select the best treatment in the fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model allows us to test several drugs and find the best therapy for each patient.

To learn more about Xenopat, click here.

Logo_ATG Therapuutics. Innovation

AtG

Atg

Suspendisse eget velit a risus efficitur tincidunt. Donec vulputate purus at sodales pellentesque. Vestibulum eu risus nulla. Praesent et lorem non tellus bibendum convallis quis vel turpis. Duis condimentum, turpis eget congue interdum, erat dolor tincidunt neque, eget iaculis urna urna convallis libero. Sed vehicula lacus quis nibh mollis dictum. Ut iaculis turpis enim, accumsan vehicula massa venenatis in. Aliquam sit amet massa accumsan, venenatis nunc at, gravida ipsum. Pellentesque sollicitudin justo sit amet orci volutpat bibendum. Nunc rutrum, tellus in laoreet varius, justo metus imperdiet purus, quis tempor mauris odio at urna. Aliquam sem metus, posuere ut mi sed, faucibus placerat libero.

To learn more about Metabostem, click here.